Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Nov 4.
Published in final edited form as: Org Lett. 2019 Feb 14;21(5):1337–1341. doi: 10.1021/acs.orglett.9b00025

Palladium-Catalyzed Methylation of Aryl, Heteroaryl, and Vinyl Boronate Esters

Alexander M Haydl 1,, John F Hartwig 1,*
PMCID: PMC6827334  NIHMSID: NIHMS1056983  PMID: 30763109

Abstract

A method for the direct methylation of aryl, heteroaryl, and vinyl boronate esters is reported, involving the reaction of iodomethane with aryl-, heteroaryl-, and vinylboronate esters catalyzed by palladium and PtBu2Me. This transformation occurs with a remarkably broad scope and is suitable for late-stage derivatization of biologically active compounds via the boronate esters. The unique capabilities of this method are demonstrated by combining carbon−boron bond-forming reactions with palladium-catalyzed methylation in a tandem transformation.

Graphical Abstract

graphic file with name nihms-1056983-f0001.jpg


Although a methyl group is the smallest alkyl group, the presence or absence of this group in a molecule can have a large effect on the medicinal activity of a compound.1 The methyl group can affect the solubility (by influencing conformation),2 selectivity for one protein over another3 and metabolic half-life,4 among other properties.5 In an extreme example, a 208-fold increase in potency of an inhibitor of p38α MAP3 kinase (5) was observed upon simple methylation (Figure 1).2a This large effect of the small methyl group has recently been coined the “magic methyl effect.”1a,b

Figure 1.

Figure 1.

(a) Examples of drugs containing carbon-bound methyl groups being important for their bioactivity. (b) An example for the magic methyl effect.

Because pharmacaphores commonly contain aromatic or heteroaromatic units and because the simple reaction of aryl organometallic reagents with methyl electrophiles generally occurs in moderate yields,6 mild, catalytic methods to attach methyl groups to arenes and heteroarenes are particularly important to develop. The classic strategies for methylation of aromatic and heteroaromatic compounds rely in many cases on either a lithium−halide exchange or an ortho-metalation of the corresponding aryl halide, followed by trapping with a methyl electrophile, such as methyl halides, triflates, or tosylates.7 Of course, this sequence requires the absence of auxiliary electrophilic and protic functional groups. Alternatively, addition of methyl radicals to arenes or heteroarenes can lead to the corresponding methyl derivatives. A protocol developed by Minisci and co-workers for methylation of electron-deficient hetereoarenes with methyl radicals leads to reaction at the electron-poor positions.8 Minisci-type C−H functionalizations conducted with photoredox catalysts and peroxo sources9 or methanol10 to form methylated heteroarenes have been reported recently11 with similar regioselectivity.

Reactions catalyzed by transition-metal complexes that form carbon−carbon bonds also can be used to prepare methylarenes and -heteroarenes. Most common is the coupling of aryl halides with a methyl nucleophile. Those couplings (X = Hal, OTf) have typically been conducted with magnesium,12 tin,13 boron,14 zinc,15 or aluminum16 reagents. Alternatively, methylation at a C−H bond catalyzed by a transition-metal complex directed by coordinating functionality has been reported.17

The coupling of an aryl nucleophile with a methyl electrophile is much less developed than the coupling of aryl electrophiles with methyl nucleophiles. The most valuable of such a reaction would occur with arylboronates, particularly arylboronate esters that are more stable than the corresponding boronic acids and can be formed by C−H bond functionalization. The coupling of arylboronic acids was first reported by Gooßen and co-workers,18a but these reactions occurred in modest yield with limited scope, and published reactions of arylboronic esters have been conducted with a large excess of the boron reagent, which would typically be the most valuable component.18b More recent methodologies reported by us18c and other groups18d rely on copper catalysts. However, applicable palladium-catalyzed solutions remain undeveloped.

We report a straightforward palladium-catalyzed methylation of aryl and heteroaryl boronate esters with methyl iodide and abundant and easily accessible boron sources. The reactions occur with low catalyst loadings, under mild conditions, with excellent functional-group tolerance, and with a simple reaction procedure that would be easily scaled. This method was successfully applied to late-stage derivatization of active pharmaceutical ingredients and, when combined with C−B bond-forming reactions, provides access to methylated compounds directly from arenes, heteroarenes, or acetylenes.

Several aspects of the reactivity of alkyl halides makes the development of coupling reactions with methyl iodide more complex that one might expect. Palladium complexes undergo oxidative addition and reductive elimination of alkyl halides more slowly than they undergo addition of aryl halides,19 and methyl electrophiles can react with phosphines to form phosphonium salts20 that would poison the catalyst. However, sterically hindered phosphines should undergo alkylation more slowly than less hindered phosphines, and strongly electron-donating phosphines should cause oxidative addition to be fast.21

Initial studies to develop synthetically useful conditions for the methylation of arenes and heteroarenes were conducted by exposing CH3I and the pinacolboronate of benzoxazole 6a, which is accessible by Ir-catalyzed C−H borylation of 2-methylbenzoxazole,22 to a series of reaction conditions (Table 1).23 The methylation product was obtained in only 48% yield under the conditions initially reported by Suzuki and coworkers (entry 1). The methylation process under these conditions was accompanied by the formation of large amounts of arene side product (27%) by protodeboronation. Variation of the conditions to improve this yield showed that the identity of the solvent was crucial to suppress the protodeboronation to form 6ab. Among various protic and aprotic polar solvents we tested (see the Supporting Information for details), reactions using the sterically hindered tert-amyl alcohol occurred in the highest yield (entry 2). Studies of the effect of the palladium precursor and studies that evaluated several classes of ligands showed that reactions catalyzed by combinations of bulky alkylphosphines and [Pd(OAc)2] as a catalytic precursor occurred in high yields, and the reaction catalyzed by PtBu2Me occurred in a high 92% yield (entry 3). Reactions conducted with palladacycle A containing this phosphine as the palladium source occurred in similar yields with a lower catalyst loading. Under the conditions of entry 5 with a catalyst loading of only 1.0 mol %, the methylated compound formed in 94% yield (entry 5).

Table 1.

Optimization of the Reaction Conditionsa

graphic file with name nihms-1056983-t0002.jpg
entry catalyst (mol %) solvent yield (6a) (%)b,c yield (6ab) (%)b
1 [Pd2(dba)3] (2.5), P(o-tolyl)3 (10) DMF/H2O (9:1) 48 27
2 [Pd(OAc)2] (5), P(o-tolyl)3 (10) TAA 75 1
3 [Pd(OAc)2] (5), PtBu2Me (10) TAA 92 <1
4 A (5) TAA 95 <1
5 A (1) TAA 94(91) <1
a

Reaction conditions: Boronate ester (0.5 mmol), KOtBu (0.6 mmol), MeI (1.0 mmol), cat. [Pd], solvent (0.1 M) at 65 °C, 18 h.

b

Yield was determined by GC using n-dodecane as the internal standard.

c

Value in parentheses is the yield of the isolated product.

d

Reaction performed with K2CO3 (2.0 equiv). Bpin = pinacolboro-nate, dba = dibenzylideneacetone, TAA = tert-amylalcohol.

The scope of the reactions with a range of benzo-fused five membered heteroarylboronates (6a−z), which are important for medicinal or agrochemistry, is shown in Scheme 1. The scope of the reactions with a range of heteroarylboronates (6a−z), which are important for medicinal or agrochemistry, is shown in Scheme 1. Reactions of such substrates derived from (di)benzofurans, (di)benzothiophenes, carbazoles, indoles, indazoles, furans and pyrazoles occurred in good to excellent yields.

Scheme 1. Methylation of Heteroaryl Boronate Estersa,b.

Scheme 1.

aYield of isolated product. bValue in parentheses is the yield determined by 1H NMR spectroscopy (using 1,3,5-trimethoxybenzene as internal standard). cReaction at 100 °C with 5.0 mol % of A.

The methylation of a series of aryl boronates containing a variety of substituents under the developed conditions are shown in Scheme 2. A wide range of functional groups in the starting material, including an alkoxy, thioalkoxy, formyl, carbamoyl, alkoxycarbonyl, cyano, nitro, trifluoromethyl, fluoro, or chloro group near the reaction site, as well as a heteroaryl substituent, were tolerated. In each case, the methylated product was obtained in excellent yield (7a−n). Furthermore, the conditions we developed for the methylation of pinacolate esters also induced the methylation of boronic acids and other commonly available boronic acid derivatives (Scheme 3).

Scheme 2. Methylation of Heteroaryl Boronate Estersa.

Scheme 2.

aYield of isolated product.

Scheme 3. Methylation of Various Boronic Acid Derivativesa.

Scheme 3.

aReaction conditions: Boronate ester (0.5 mmol), KOtBu (0.6 mmol), MeI (1.0 mmol), A (1.0 mol %), tert-amylalcohol (0.1 M) at 65 °C, 18 h. bYield of isolated product. cRatio was determined by GC.

In addition to the methylation of aryl and heteroarylboronates, the methylation of vinyl boronate esters occurred in high yield with substrates bearing aromatic, heteroaromatic, or aliphatic moieties connected to the double bond (8a−h; Scheme 4). These reactions enabled the stereoselective synthesis of trisubstituted double bonds (8g and 8h) in high yield, while retaining the E or Z configuration of the alkene unit. Classical approaches to prepare trisubstituted alkenes in which one of the groups is a methyl group typically involve multiple synthetic operations and occur with moderate stereoselectivity.24

Scheme 4. Methylation of Vinyl Boronate Estersa.

Scheme 4.

aYield of isolated product. bReaction with 5.0 mol % of A.

Having established the exceptional functional-group tolerance and broad scope of arenes and heteroarenes, we assessed the methylation process for the late-stage derivatization of active pharmaceutical ingredients and pharmaceutical candidates (9a−h; Scheme 5). Indeed, methylation of the eight pinacolboronates in Scheme 5 derived from active pharmaceutical ingredients occurred in good to excellent yields.

Scheme 5. Late-Stage Methylation of Complex and Bioactive Moleculesa.

Scheme 5.

aYield of isolated product. bReaction with the B(neop) precursor. cReaction performed in 0.2 mmol scale.

The value of this process is further demonstrated by combining the methylation with C−B bond-forming reactions. These C−B bond-forming reactions include iridium-catalyzed C−H borylation of arenes and heteroarenes,25 as well as stereoselective hydroboration,26,27 and carbaboration of alkynes (Scheme 6).28 A two-step processes involving generation of an aryl or heteroaryl boronate ester and methylation of the boronate intermediate in one pot without purification of the boronate provided methylated arenes (7l) and heteroarenes (1b and 10) in good yield, including two examples on the 700 mg to gram scale. Likewise, the stereoselective hydroboration of terminal or internal alkynes, followed by subsequent methylation, led to (E)-alkenes (8b and 8d) selectively, and the regioselective carboboration of terminal alkynes, followed by palladium-catalyzed methylation of the resulting vinylboronate, generated a trisubstituted methylalkene (8h) with high stereoselectivity in good yield, directly from its corresponding alkyne.

Scheme 6. Methylation of Arenes, Heteroarenes and Alkynes via One-Pot C−B Bond-Forming Reaction, Followed by Methylation.

Scheme 6.

a(a) [{Ir(cod)OMe}2] (1.0 mol %), dtbpy (2.0 mol %), B2pin2, THF, 80 °C, 18 h then solvent removed; (b) A (1.0 mol %), KOtBu, MeI, tert-amylalcohol, 65 °C, 18 h; (c) [{Ir(cod)OMe}2] (0.5 mol %),Me4phen (1.0 mol %), B2pin2, THF, room temperature, 18 h then solvent removed; (d) [Ru(PPh3)3(CO)HCl] (5.0 mol %), HBpin, toluene, 50 °C, 16 h then solvent removed; (e) [{RuCp*(MeCN)3}-PF6] (5.0 mol %), HBpin, CH2Cl2, room temperature, 3 h then solvent removed; (f) CuCl (15 mol %), Xantphos (15 mol %), KOtBu, B2pin2, MeI, THF, 50 °C then solvent removed. B2pin2 =bispinacolatodiboron, dtbpy = 4,4′-Di-tert-butyl-2,2′-bipyridine, Cp* = pentamethylcyclopentadiene, phen = phenanthroline.

In conclusion, an efficient method for the methylation of arylboronic acid esters has been developed with CH3I as the source of the methyl group under mild conditions. The methylation proceeds with high functional-group compatibility and a broad scope of arenes, heteroarenes, and alkenes and is suitable for late-stage functionalization of complex structures. Sequential, one-pot processes allow the methylation of arenes, heteroarenes, and alkenes to occur through aryl or vinyl boronate ester intermediates generated in situ.

Supplementary Material

SI

ACKNOWLEDGMENTS

We are thankful for support from the NIH (GM-115812 and R35GM130387) and a DAAD Postdoc Fellowship (A.M.H.). A.M.H. thanks Dr. Ruth Dorel, Dr. Haoquan Li, and Isabell Ohmberger for insightful discussions at U.C. Berkeley. Christian Bold is acknowledged for preliminary experimental work at U. C. Berkeley on this project.

Footnotes

The authors declare no competing financial interest.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.9b00025.

All synthetic procedures for new compounds as well as their analytical data, involving 1H NMR, 13C NMR spectra (PDF)

REFERENCES

  • (1).(a) Barreiro EJ; Kummerle AE; Fraga CAM Chem. Rev 2011, 111, 5215–5246. [DOI] [PubMed] [Google Scholar]; (b) Schönherr H; Cernak T Angew. Chem., Int. Ed 2013, 52, 12256–12267; [DOI] [PubMed] [Google Scholar]; Angew. Chem 2013, 125, 12480–12492. [Google Scholar]; (c) Bazzini P; Wermuth CG The Practice of Medicinal Chemistry, 3rd ed.; Wermuth CG, Ed.; Academic Press: San Diego, 2008; pp 431–418. [Google Scholar]; (d) Andrews PR; Craik DJ; Martin JL J. Med. Chem 1984, 27, 1648–1657. [DOI] [PubMed] [Google Scholar]
  • (2).(a) Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL Bioorg. Med. Chem. Lett 2008, 18, 4428–4432. [DOI] [PubMed] [Google Scholar]; (b) Ginnings PM; Baum R J. Am. Chem. Soc 1937, 59, 1111. [Google Scholar]; (c) Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey A-M; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ J. Med. Chem 2011, 54, 4880–4895. [DOI] [PubMed] [Google Scholar]
  • (3).(a) Li L; Beaulieu C; Carriere M-C; Denis D; Greig G; Guay D; O’Neill G; Zamboni R; Wang Z Bioorg. Med. Chem. Lett 2010, 20, 7462–7465. [DOI] [PubMed] [Google Scholar]; (b) Shamovsky I; de Graaf C; Alderin L; Bengtsson M; Bladh H; Börjesson L; Connolly S; Dyke HJ; van den Heuvel M; Johansson H; Josefsson B-G; Kristoffersson A; Linnanen T; Lisius A; Männikköo R; Nordén B; Price S; Ripa L; Rognan D; Rosendahl A; Skrinjar M; Urbahns K J. Med. Chem 2009, 52, 7706–7723. [DOI] [PubMed] [Google Scholar]; (c) Bencsik JR; Xiao D; Blake JF; Kallan NC; Mitchell IS; Spencer KL; Xu R; Gloor SL; Martinson M; Risom T; Woessner RD; Dizona F; Wua W-I; Vigers GPA; Brandhuber BJ; Skelton NJ; Prior WW; Murray LJ Bioorg. Med. Chem. Lett 2010, 20, 7037–7041. [DOI] [PubMed] [Google Scholar]
  • (4).(a) Alberts AW; Chen J; Kuron G; Hunt V; Huff J; Hoffman C; Rothrock J; Lopez M; Joshua H; Harris E; Patchett A; Monaghan R; Currie S; Stapley E; Albers-Schonberg G; Hensens O; Hirshfield J; Hoogsteen K; Liesch J; Springer J Proc. Natl. Acad. Sci. U. S. A 1980, 77, 3957–3961. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Endo A J. Antibiot 1980, 33, 334–336. [DOI] [PubMed] [Google Scholar]; (c) Hoffman WF; Alberts AW; Anderson PS; Chen JS; Smith RL; Willard AK J. Med. Chem 1986, 29, 849–852. [DOI] [PubMed] [Google Scholar]
  • (5).(a) Goodman AJ; Le Bourdonnec B; Dolle RE ChemMedChem 2007, 2, 1552–1570. [DOI] [PubMed] [Google Scholar]; (b) McElvain SM; Clemens DH J. Am. Chem. Soc 1958, 80, 3915–3923. [Google Scholar]; (c) Wood MR; Hopkins CR; Brogan JT; Conn PJ; Lindsley CW Biochemistry 2011, 50, 2403–2410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (6).(a) Aguilar D; Fernández I; Cuesta L; Yañez-Rodríguez V; Soler T; Navarro R; Urriolabeitia EP; Ortiz FL J. Org. Chem 2010, 75, 6452–6462. [DOI] [PubMed] [Google Scholar]; (b) Meyer N; Seebach D Chem. Ber 1980, 113, 1304–1319. [Google Scholar]; (c) Meyers AI; Pansegrau PD Tetrahedron Lett. 1983, 24, 4935–4938. [Google Scholar]
  • (7).(a) Snieckus V Chem. Rev 1990, 90, 879–933. [Google Scholar]; (b) Townsend CA; Bloom LM Tetrahedron Lett. 1981, 22, 3923–3924. [Google Scholar]
  • (8).(a) Minisci F; Bernardi R; Bertini F; Galli R; Perchinummo M Tetrahedron 1971, 27, 3575–3579. [Google Scholar]; (b) Minisci F; Galli R; Cecere M; Malatesta V; Caronna T Tetrahedron Lett. 1968, 9, 5609–5612. [Google Scholar]; (c) Punta C; Minisci F Trends Heterocycl. Chem 2008, 13, 1–68. [Google Scholar]
  • (9).(a) Ahn SK; Choi NS; Jeong BS; Kim KK; Journ DJ; Kim JK; Lee SJ; Kim JW; Hong C; Jew S-SJ J. Heterocycl. Chem 2000, 37, 1141–1144. [Google Scholar]; (b) DiRocco DA; Dykstra K; Krska S; Vachal P; Conway DV; Tudge M Angew. Chem., Int. Ed 2014, 53, 4802–4806; Angew. Chem. 2014, 126, 4902−4906. [DOI] [PubMed] [Google Scholar]; (c) Gui J; Zhou Q; Pan C-M; Yabe Y; Burns AC; Collins MR; Ornelas MA; Ishihara Y; Baran PS J. Am. Chem. Soc 2014, 136, 4853–4856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (10).(a) Jin J; MacMillan DWC Nature 2015, 525, 87–90. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Natte K; Neumann H; Beller M; Jagadeesh RV Angew. Chem., Int. Ed 2017, 56, 6384–6394; Angew. Chem. 2017, 129, 6482−6492. [DOI] [PubMed] [Google Scholar]
  • (11).Serpier F; Pan F; Ham WS; Jacq J; Genicot C; Ritter T Angew. Chem., Int. Ed 2018, 57, 10697–10701. [DOI] [PubMed] [Google Scholar]
  • (12).(a) Agrawal T; Cook SP Org. Lett 2014, 16, 5080–5083. [DOI] [PubMed] [Google Scholar]; (b) Sun CL; Fürstner A Angew. Chem., Int. Ed 2013, 52, 13071–13075; Angew. Chem. 2013, 125, 13309−13313. [DOI] [PubMed] [Google Scholar]; (c) Chen Q; Ilies L; Yoshikai N; Nakamura E Org. Lett 2011, 13, 3232–3234. [DOI] [PubMed] [Google Scholar]
  • (13).Chen X; Li J; Hao X; Goodhue CE; Yu J-Q J. Am. Chem. Soc 2006, 128, 78–79. [DOI] [PubMed] [Google Scholar]
  • (14).(a) Chen X; Goodhue CE; Yu J-Q J. Am. Chem. Soc 2006, 128, 12634–12635. [DOI] [PubMed] [Google Scholar]; (b) Giri R; Maugel N; Li J-J; Wang D-H; Breazzano SP; Saunders LB; Yu J-Q J. Am. Chem. Soc 2007, 129, 3510–3511. [DOI] [PubMed] [Google Scholar]; (c) Dai H-X; Stepan AF; Plummer MS; Zhang Y-H; Yu J-Q J. Am. Chem. Soc 2011, 133, 7222–7228. [DOI] [PubMed] [Google Scholar]; (d) Thuy-Boun PS; Villa G; Dang D; Richardson P; Su S; Yu J-Q J. Am. Chem. Soc 2013, 135, 17508–17513. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Romero-Revilla JA; García-Rubia A; Arrayás RG; Fernández-Ibánez MÁ; Carretero JC J. Org. Chem 2011, 76, 9525–9530. [DOI] [PubMed] [Google Scholar]; (f) Neufeldt SR; Seigerman CK; Sanford MS Org. Lett 2013, 15, 2302–2305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (15).(a) Wang T; Alfonso BJ; Love JA Org. Lett 2007, 9, 5629–5631. [DOI] [PubMed] [Google Scholar]; (b) Herbert JM Tetrahedron Lett. 2004, 45, 817–819. [Google Scholar]
  • (16).(a) Cooper T; Novak A; Humphreys LD; Walker MD; Woodward S Adv. Synth. Catal 2006, 348, 686–690. [Google Scholar]; (b) Shang R; Ilies L; Nakamura E J. Am. Chem. Soc 2015, 137, 7660–7663. [DOI] [PubMed] [Google Scholar]
  • (17).(a) Tonin MDL; Zell D; Müller V; Ackermann L Synthesis 2016, 49, 127–134. [Google Scholar]; (b) Giri R; Maugel NL; Li J-J; Wang D-H; Breazzano SP; Saunders LB; Yu J-Q J. Am. Chem. Soc 2007, 129, 3510–3511. [DOI] [PubMed] [Google Scholar]; (c) Chen X; Goodhue CE; Yu J-Q J. Am. Chem. Soc 2006, 128, 12634–12635. [DOI] [PubMed] [Google Scholar]; (d) Cheng G; Wang P; Yu J-Q Angew. Chem., Int. Ed 2017, 56, 8183–8186; Angew. Chem. 2017, 129, 8295−8298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (18).(a) Gooßen LJ Appl. Organomet. Chem 2004, 18, 602–604. [Google Scholar]; (b) Doi H; Ban I; Suzuki M Chem. - Eur. J 2009, 15, 4165–4171. [DOI] [PubMed] [Google Scholar]; (c) He Z-T; Li H; Haydl AM; Whiteker GT; Hartwig JF J. Am. Chem. Soc 2018, 140, 17197–17202. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Yang CT; Zhang ZQ; Liu YC; Liu L Angew. Chem., Int. Ed 2011, 50, 3904–3907. [DOI] [PubMed] [Google Scholar]
  • (19).(a) Luh T-Y; Leung M-K; Wong K-T Chem. Rev 2000, 100, 3187–3204. [DOI] [PubMed] [Google Scholar]; (b) Cardenas DJ Angew. Chem., Int. Ed 1999, 38, 3018–3020; Angew. Chem. 1999, 111, 3201−3203. [DOI] [PubMed] [Google Scholar]; (c) Kirchhoff JH; Netherton MR; Hills ID; Fu GC J. Am. Chem. Soc 2002, 124, 13662–13663. [DOI] [PubMed] [Google Scholar]; (d) Kirchhoff JH; Dai C; Fu GC Angew. Chem., Int. Ed 2002, 41, 1945–1947; Angew. Chem. 2002, 114, 2025−2027. [PubMed] [Google Scholar]; (e) Netherton MR; Fu GC Angew. Chem., Int. Ed 2002, 41, 3910–3912; Angew. Chem. 2002, 114, 4066−4068. [DOI] [PubMed] [Google Scholar]
  • (20).Allen DW In Organophosphorus Chemistry: Phosphines and related P−C-bonded compounds, Vol. 43; Tebby JC, Loakes D, Allen DW, Eds.; Royal Society of Chemistry: London, 2014; pp 1–51. [Google Scholar]
  • (21).Hartwig JF In Organotransition Metal Chemistry - From Bonding to Catalysis; Hartwig JF, Ed.; University Science Books: Sausalito, CA, 2010; pp 261–320. [Google Scholar]
  • (22).Larsen MA; Hartwig JF J. Am. Chem. Soc 2014, 136, 4287–4299. [DOI] [PubMed] [Google Scholar]
  • (23).For further information, see Supporting Information.
  • (24).(a) Haydl AM; Berthold D; Spreider PA; Breit B Angew. Chem., Int. Ed 2016, 55, 5765–5769; Angew. Chem. 2016, 128, 5859−5863. [DOI] [PubMed] [Google Scholar]; (b) Liniger M; Liu Y; Stoltz BM J. Am. Chem. Soc 2017, 139, 13944–13949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (25).(a) Litvinas ND; Fier PS; Hartwig JF Angew. Chem., Int. Ed 2012, 51, 536–539; Angew. Chem. 2012, 124, 551−554. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Robbins DW; Hartwig JF Angew. Chem., Int. Ed 2013, 52, 933–937; Angew. Chem. 2013, 125, 967−971. [DOI] [PubMed] [Google Scholar]; (c) Partridge BM; Hartwig JF Org. Lett 2013, 15, 140–143 and [DOI] [PubMed] [Google Scholar]; ref 21.
  • (26).Yasu Y; Koike T; Akita M Chem. Commun 2013, 49, 2037–2039. [DOI] [PubMed] [Google Scholar]
  • (27).Sundararaju B; Fürstner A Angew. Chem., Int. Ed 2013, 52, 14050–14054; Angew. Chem. 2013, 125, 14300−14304. [DOI] [PubMed] [Google Scholar]
  • (28).Alfaro R; Parra A; Alemán J; Ruano JLG; Tortosa M J.Am. Chem. Soc 2012, 134, 15165–15168. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

SI

RESOURCES